Treatment and delay of outset of Parkinson's disease
AssigneesJanssen Alzheimer Immunotherapy, The Regents of the University of California
InventorsDale B. Schenk, Eliezer Masliah
Life of this patent
Estimating the term…
Abstract
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Claims24
A method of therapeutically treating a patient suffering from Parkinson's disease, the method comprising
- administering to the patient an effective regime of an agent and thereby therapeutically treating the disease;
- wherein (i) the agent is Aβ or an immunogenic fragment thereof and the agent is linked to a carrier that helps elicit an immune response to the agent or is administered with an adjuvant that augments an immune response to the agent, or (ii) the agent is an antibody to Aβ.
A method of therapeutically treating a patient suffering from Parkinson's disease, comprising
- administering to the patient an effective regime of a first agent and a second agent and thereby therapeutically treating the disease;
- wherein (i) the first agent is alpha synuclein or an immunogenic fragment thereof, and the first agent is linked to a carrier that helps elicit an immune response to the first agent or is administered with an adjuvant that augments an immune response to the first agent, or (ii) the first agent is an antibody to alpha synuclein, and
- wherein (i) the second agent is Aβ or an immunogenic fragment thereof and the second agent is linked to a carrier that helps elicit an immune response to the second agent or is administered with an adjuvant that augments an immune response to the second agent, or (ii) the second agent is an antibody to Aβ.
A method of reducing the risk, lessening the severity, or delaying the outset of disease in a patient having a known genetic risk of Parkinson's disease, the method comprising
- administering to the patient an effective regime of an agent and thereby reducing the risk, lessening the severity, or delaying the outset of the disease;
- wherein (i) the agent is Aβ or an immunogenic fragment thereof, and the agent is linked to a carrier that helps elicit an immune response to the agent or is administered with an adjuvant that augments an immune response to the agent, or (ii) the agent is an antibody to Aβ.
A method of reducing the risk, lessening the severity, or delaying the outset of disease in a patient having a known genetic risk of Parkinson's disease, comprising
- administering to the patient an effective regime of a first agent and a second agent that induces an immunogenic response against Aβ in the patient and thereby reducing the risk, lessening the severity, or delaying the outset of the disease;
- wherein (i) the first agent is alpha synuclein or an immunogenic fragment thereof and the first agent is linked to a carrier that helps elicit an immune response to the first agent or is administered with an adjuvant that augments an immune response to the first agent, or (ii) the first agent is an antibody to alpha synuclein, and
- wherein (i) the second agent is Aβ or an immunogenic fragment thereof and the second agent is linked to a carrier that helps elicit an immune response to the second agent or is administered with an adjuvant that augments an immune response to the second agent, or (ii) the second agent is an antibody to Aβ.
Dependencies are inferred from the claim text.